LBS-Neurons For Treating Stroke

July 01, 1998

Physicians at the University of Pittsburgh Medical Center (UPMC) are evaluating the use of LBS-Neurons in the world's first clinical human neuron transplant into a patient's brain. This is the first effort to treat stroke patients with an intracerebral graft of cells. These neurons are provided by Layton BioScience, Inc., located in Atherton, Cal. Specifically, the Pitt research team expects the LBS-neurons to improve the function of neurons damaged after a stroke. Based on previous studies with an animal model of stroke, researchers think that grafted LBS-Neurons will either enhance the function of host neurons that survive a stroke but are impaired, or replace host neurons that have been destroyed by a stroke.

The LBS-Neurons are derived from a cell line initially developed in the mid-1980s and manipulated further in tissue culture and in animal models by several research teams from the late 1980s onward.

LBS-Neurons originate from a human teratocarcinoma found in a 22-year-old cancer patient. Teratocarcinomas are tumors of the reproductive organs that are composed of embryonic-like cells. Researchers at the University of Pennsylvania perfected and patented a process that uses several chemicals to cleverly transform this rapidly dividing cell line into fully differentiated, non-dividing neurons. They have accomplished this by treating the parent cells with retinoic acid, a biological agent known to induce the maturation of cancer cells into their normal-looking, noncancerous equivalents. This procedure has been used in other circumstances.

For example, cancer investigators have used retinoic acid to transform cancer cells in tumors of the head and neck cancer into benign or non-tumor cells as a therapy. Because teratocarcinomas contain cells that are embryonic in nature, they have the capacity to respond to treatment with specific chemicals by progressively developing into different cell types. Remarkably, the Layton BioScience line of teratocarcinoma cells obtained from the young patient differentiated into non-dividing neurons in response to the treatment discovered by the Penn researchers.

At the University of Pennsylvania, initial experiments using cultured LBS-Neurons revealed that they could thrive as transplants within normal rodent brains, as well as within stroke-damaged brain regions of rats. Researchers at Penn found that the LBS-neuron transplants within normal rodent brains integrated with existing neurons, produced other neuronal proteins and formed synapses.

Moreover, researchers investigating LBS-Neuron transplants in rodents found that these transferred cells started to look and function like the type of neurons near the insertion site. Thus, LBS-Neurons transplanted in the brain cortex became cortical neurons, whereas LBS-Neurons transplanted into deep brain regions resembled their neighbors. In some experiments, rats with LBS-Neuron grafts also received the immune-suppressing drug cyclosporin to block transplant rejection and promote the survival of the LBS-Neuron transplants for more than a year. However, grafts into the brains of mice with a limited functioning immune system also survived over one year without drugs to suppress the immune system.

Later experiments performed by other researchers at the University of South Florida showed that LBS-Neurons could correct cognitive deficits and motor skill problems associated with stroke-induced brain injury in rats. Significantly, all of these studies showed that the LBS-Neurons did not revert to cancer cells or cause tumors in any experimental animals.

In the current clinical trial at UPMC, investigators performed a single surgical procedure to deliver 2 million cells divided among three sites within and around the stroke-damaged tissue of the patient's brain.

Once implanted into and around the stroke, the LBS-Neurons are expected to integrate with existing tissue. There, they may restore brain function by interacting with the remaining neurons by mechanisms that are unknown, but which are under intense study.

The Pitt clinical investigators led by Douglas Kondziolka, M.D., and Lawrence Wechsler, M.D., will assess the activity of the implanted neurons 24 weeks after transplant using positron emission tomography, or PET, which will measure the metabolic activity, if any, in the area of the implanted nerve cells. Magnetic resonance imaging (MRI) sequences performed at 4 and 24 weeks after the transplant also will allow investigators to study the grafted brain site. In addition, the researchers will monitor blood levels of chemicals to assess for any adverse effects.

The use of LBS-Neurons in this clinical study obviates the need to use fetal cells, the other primary cell type being studied for transplant into the brain for a variety of other neurological disorders, such as Parkinson's disease and Huntington's disease. The harvesting of fetal human cells for treating disease has raised ethical concerns, especially regarding elective abortions. On the other hand, spontaneous abortions are rare and unpredictable events, so harvesting tissues from these fetuses would prove impractical. Further, cells from spontaneously aborted fetuses would be more likely to contain serious genetic defects.

The use of fetal animal cells has also been questioned, because cross-species transplantation involves animal tissue cells that carry very different immune markers from human tissue cells. Thus, cross-species immune rejection of the transplanted cells is likely. Moreover, fetal animal cells may contain as-yet unknown infectious diseases that could crossover into the recipient's tissue.

Another important feature of LBS-Neurons is that they can be frozen and transported to clinical centers for transplantation, whereas fresh (non-frozen) fetal cell cultures are used for transplantation. That LBS-neurons can be frozen, thawed and inserted into living brains at all is impressive. To date, researchers worldwide have been unable to achieve this level of progress with any other neuron cell line.

Many investigators contributed important pre-clinical research findings that made possible this historic clinical neuron transplant for stroke. For additional information about the history of the development and testing of LBS-Neurons, the pre-clinical application of LBS-Neurons to other disease processes and a corporate profile of Layton BioScience, Inc., please visit

For additional information about the role of these neurons in the clinical trial, please look in the News Bureau section of UPMC Health System's web page,

University of Pittsburgh Medical Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to